Experience with Rituximab from observational studies

US POMS cohort

In 56 patients 62% reduction in relapses when compared with first-line injectables

SWEDISH POMS cohort

14 patients median period of 23.6 months, a stable disease was observed in 13/14 patients (93%)

Side effects were similar with infusion-induced reactions being the most common, followed by rashes and fewer

Krysko KM, Graves JS, Rensel M, Weinstock-Guttman B, Rutatangwa A, Aaen G, et al. Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis. Ann Neurol. 2020;88(1):42–55 ; Salzer J, Lycke J, Wickstrom R, Naver H, Piehl F, Svenningsson A. Rituximab in paediatric onset multiple sclerosis: a case series. J Neurol. 2016;